Controlled trial of nifedipine and bendroflumethiazide in hypertension

J Cardiovasc Pharmacol. Nov-Dec 1983;5(6):1083-5. doi: 10.1097/00005344-198311000-00025.


In a double-blind study 30 patients with mild or moderate (World Health Organization classification I or II) hypertension were treated with either nifedipine, 20 mg twice a day, or bendroflumethiazide, 2.5 mg (+0.57 g KCl) twice a day for 24 weeks. All patients were then given a combination of half the initial dosage of both drugs for an additional period of 6 weeks. Nifedipine caused a significant reduction of both supine and standing blood pressures (16/10 and 11/5 mm Hg, respectively). Bendroflumethiazide also reduced both recumbent and standing blood pressures significantly (15/10 and 11/10 mm Hg, respectively). Combined treatment with nifedipine and bendroflumethiazide caused a further reduction of both supine and standing blood pressures. The total reduction compared with placebo was 23/12 mm Hg (p less than 0.001) and 17/11 mm Hg (p less than 0.001), respectively. There was no significant correlation between antihypertensive effect and age of patient.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Bendroflumethiazide / adverse effects
  • Bendroflumethiazide / therapeutic use*
  • Blood Pressure / drug effects
  • Clinical Trials as Topic
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Heart Rate / drug effects
  • Humans
  • Hypertension / drug therapy*
  • Male
  • Middle Aged
  • Nifedipine / adverse effects
  • Nifedipine / therapeutic use*


  • Bendroflumethiazide
  • Nifedipine